
InterventionalCardiologist @LVHN @TJUHospital; #ClinicalInformatics; Alum @HopkinsMedicine; #OslerPride; @HopkinsHeart; https://nitter.cf/t.co/SQ6WBL4Ewc; #AI; #Cell
- Tweets11.9K
- Following3.9K
- Followers1.9K
- Likes4.4K

ALT A table showing the clinical end points at 1 year (intention-to-treat analysis). It compares two groups: Ticagrelor-Policy Group (9444 patients) and Prasugrel-Policy Group (7651 patients). Primary end point shows 1113 events in the Ticagrelor-Policy Group and 848 in the Prasugrel-Policy Group. Secondary end points are listed, including death from any cause, myocardial infarction, stroke, major bleeding, and stent thrombosis, with corresponding patient numbers and percentages for each group. Odds ratios with confidence intervals are provided.

ALT Chart titled "The ASAP-TOO Trial: LAAC vs Non-OAC Therapy in Anticoagulation-Ineligible AF." The image shows a flowchart with three main sections. The left section illustrates high-risk AF population details and includes heart anatomy. The center section outlines the randomized ASAP-TOO trial design, highlighting the WATCHMAN 2.5 Device, and lists enrollment numbers and clinical outcomes followed up to five years. The right section displays a summary of 5-year outcomes, including primary effectiveness, safety, stroke severity, and other outcomes with percentage and quantitative data. The chart footer includes citation information for the study.

ALT A graph from the Original Article "Left Bundle-Branch Pacing versus Right Ventricular Pacing for Atrioventricular Block.โ The trial name, OptimPacing, is in parentheses after the title. The graph shows the primary outcome. The trial results are being presented at the American Heart Association Scientific Sessions 2026. The logo of the New England Journal of Medicine is at the bottom.

ALT Glucagon-like peptideโ1 (GLP-1) receptor agonists are among the most effective treatments for obesity and other metabolic disorders. With widespread use of these drugs, it has become clear that their effects go well beyond health conditions traditionally linked to metabolism, affecting multiple other organ systems, particularly the brain. Continued research in this field has also expanded beyond the GLP-1 receptor as a target, with the development of additional drugs and combinations to help optimize patient care. Illustration: C. Bickel/Science






























